Global Malignant Mesothelioma Therapeutics Market 2019-2023
SKU ID : TNV-14462810 | Publishing Date : 16-Jul-2019 | No. of pages : 125
Detailed TOC of Global Malignant Mesothelioma Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Chemotherapy - Market size and forecast 2018-2023
Other therapeutics - Market size and forecast 2018-2023
Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 11: MARKET TRENDS
Increasing awareness of malignant mesothelioma
Development of novel therapies
Reimbursement policies for chemotherapy
PART 12: VENDOR LANDSCAPE
Overview
Landscape disruption
PART 13: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Bristol-Myers Squibb Co.
Eli Lilly and Co.
F. Hoffmann-La Roche Ltd.
Merck & Co. Inc.
Pfizer Inc.
PART 14: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 15: EXPLORE TECHNAVIO
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Product - Market share 2018-2023 (%)
Exhibit 18: Comparison by product
Exhibit 19: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Chemotherapy - Year-over-year growth 2019-2023 (%)
Exhibit 21: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Other therapeutics - Year-over-year growth 2019-2023 (%)
Exhibit 23: Market opportunity by product
Exhibit 24: Customer landscape
Exhibit 25: Market share by geography 2018-2023 (%)
Exhibit 26: Geographic comparison
Exhibit 27: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: North America - Year-over-year growth 2019-2023 (%)
Exhibit 29: Top 3 countries in North America
Exhibit 30: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 32: Top 3 countries in Europe
Exhibit 33: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in Asia
Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in ROW
Exhibit 39: Key leading countries
Exhibit 40: Market opportunity
Exhibit 41: Drug designations
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 49: Bristol-Myers Squibb Co. - Product segments
Exhibit 50: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 51: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 52: Bristol-Myers Squibb Co. - Key offerings
Exhibit 53: Bristol-Myers Squibb Co. - Key customers
Exhibit 54: Eli Lilly and Co. - Vendor overview
Exhibit 55: Eli Lilly and Co. - Business segments
Exhibit 56: Eli Lilly and Co. - Organizational developments
Exhibit 57: Eli Lilly and Co. - Geographic focus
Exhibit 58: Eli Lilly and Co. - Segment focus
Exhibit 59: Eli Lilly and Co. - Key offerings
Exhibit 60: Eli Lilly and Co. - Key customers
Exhibit 61: F. Hoffmann-La Roche Ltd. - Vendor overview
Exhibit 62: F. Hoffmann-La Roche Ltd. - Business segments
Exhibit 63: F. Hoffmann-La Roche Ltd. - Organizational developments
Exhibit 64: F. Hoffmann-La Roche Ltd. - Geographic focus
Exhibit 65: F. Hoffmann-La Roche Ltd. - Segment focus
Exhibit 66: F. Hoffmann-La Roche Ltd. - Key offerings
Exhibit 67: F. Hoffmann-La Roche Ltd. - Key customers
Exhibit 68: Merck & Co. Inc. - Vendor overview
Exhibit 69: Merck & Co. Inc. - Business segments
Exhibit 70: Merck & Co. Inc. - Organizational developments
Exhibit 71: Merck & Co. Inc. - Geographic focus
Exhibit 72: Merck & Co. Inc. - Segment focus
Exhibit 73: Merck & Co. Inc. - Key offerings
Exhibit 74: Merck & Co. Inc. - Key customers
Exhibit 75: Pfizer Inc. - Vendor overview
Exhibit 76: Pfizer Inc. - Business segments
Exhibit 77: Pfizer Inc. - Organizational developments
Exhibit 78: Pfizer Inc. - Geographic focus
Exhibit 79: Pfizer Inc. - Segment focus
Exhibit 80: Pfizer Inc. - Key offerings
Exhibit 81: Pfizer Inc. - Key customers
Exhibit 82: Validation techniques employed for market sizing
Exhibit 83: Definition of market positioning of vendors